Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Summary of Position:
Scholar Rock is seeking an outstanding individual to play a key role in the discovery and development of novel biotherapeutics. The successful candidate will join the Antibody Engineering group to discover, express, purify, and characterize antibodies and other biologic modalities to support multiple discovery programs.
Position Responsibilities:
- Utilize a proprietary in-house phage display platform to discover novel candidate antibodies
- Design antigens and potential therapeutic molecules and engineer lead candidates
- Conduct experiments to evaluate the 'drug-like' quality of candidate antibodies
- Perform Octet, Biacore, and ELISA experiments to evaluate the binding profile and affinity of lead molecules
- Evaluate and implement new technologies for efficient and high-throughput screening of antibodies and antibody fragments
- Perform purification of antibodies and other proteins at various production scales
- Maintain detailed records of experimental protocols and data in laboratory notebooks in accordance with company policy
- Analyze, interpret, report, and present experimental results
Candidate Requirements:
- Ph.D. in molecular biology, biochemistry, or related field with 0-1 year of industry experience or BS/MS with comparable pharmaceutical industry experience
- Experience engineering antibodies and/or peptides preferred
- Strong written and verbal communication skills
- The individual should be able to function in a timeline-driven, dynamic environment, and be able to rapidly adapt to new techniques and protocols
- The successful candidate should have the ability to work both independently and as part of a team to meet deadlines and contribute to the strategic goals of the company
- Flexibility to work in a matrixed research organization
- A strong work ethic and high-level of motivation are required
Scholar Rock is an Equal Opportunity Employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
Top Skills
What We Do
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/
For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy